10-Q: Achieve Life Sciences Files NDA for Cytisinicline

Achieve Life Sciences submitted its New Drug Application for cytisinicline for smoking cessation and secured significant funding, extending its cash runway into late 2026.

Summary

• Achieve Life Sciences, a late-stage clinical specialty pharmaceutical company, submitted a New Drug Application (NDA) to the FDA in June 2025 for cytisinicline as a treatment for smoking cessation in adults.
• The company received Breakthrough Therapy designation from the FDA for cytisinicline for nicotine e-cigarette, or vaping, cessation in the third quarter of 2024.
• Achieve completed enrollment for its ORCA-OL open-label safety trial in October 2024, meeting FDA requirements for long-term safety exposure data with 300 subjects completing six months of treatment by January 2025 and 100 subjects completing one year by April 2025.
• Net loss for the six months ended June 30, 2025, increased to $25.5 million, up from $14.9 million for the same period in 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, was $20.2 million, compared to $10.2 million for the same period in 2024.
• The company raised approximately $41.2 million in net proceeds from a public offering in June 2025, selling 15,000,000 shares of common stock and accompanying warrants at $3.00 per unit.
• As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $55.4 million, with a positive working capital balance of $48.3 million.
• The company believes its existing capital will fund operations into the second half of 2026.
• Achieve entered into a New Convertible Term Loan agreement in July 2024 for $10.0 million, with potential for an additional $10.0 million in tranches contingent on FDA NDA acceptance and lender discretion.
• A dispute exists with Sopharma, the cytisinicline supplier, regarding Achieve's engagement of third-party manufacturers, which Sopharma alleges is a breach of their agreement.

Sentiment

Score: 7

Explanation: The company achieved significant milestones with the NDA submission for smoking cessation and Breakthrough Therapy designation for vaping cessation, substantially de-risking its primary asset. The successful capital raise provides a runway into H2 2026, addressing immediate liquidity concerns. While operating losses increased, this is expected for a development-stage biotech advancing its product. The Sopharma dispute and reliance on a single product are notable risks, but the overall progress and strengthened financial position are positive for its stage.

Positives

• Submitted a New Drug Application (NDA) to the FDA for cytisinicline for smoking cessation in June 2025, a major regulatory milestone.
• Received Breakthrough Therapy designation from the FDA for cytisinicline for nicotine e-cigarette (vaping) cessation in Q3 2024, potentially expediting development and review.
• Achieved key safety data milestones for the ORCA-OL trial, with 300 subjects completing six months of cytisinicline exposure by January 2025 and 100 subjects completing one year by April 2025.
• Successfully raised $41.2 million in net proceeds from a public offering in June 2025, significantly bolstering liquidity.
• Refinanced debt with a New Convertible Term Loan of $10.0 million, with potential for an additional $10.0 million, providing flexible financing.
• Maintained a strong cash position with $55.4 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
• Reported a positive working capital balance of $48.3 million, indicating short-term financial health.
• Planned commercial launch of cytisinicline in the U.S. in the second half of 2026, if approved, with a strategy leveraging AI tools and an integrated agency partnership (Omnicom).

Negatives

• Incurred an accumulated deficit of $231.1 million as of June 30, 2025, reflecting historical and ongoing operating losses.
• Net loss for the six months ended June 30, 2025, increased significantly to $25.5 million from $14.9 million in the prior year period.
• Net cash used in operating activities more than doubled to $20.2 million for the six months ended June 30, 2025, compared to $10.2 million in the prior year, indicating increased cash burn.
• Research and development expenses increased to $13.8 million for the six months ended June 30, 2025, from $7.9 million in the prior year, driven by the ORCA-OL trial.
• General and administrative expenses increased to $11.7 million for the six months ended June 30, 2025, from $6.5 million in the prior year, primarily due to higher employee and commercial launch preparation costs.
• The company is dependent on a single product candidate, cytisinicline, making its business highly vulnerable to the success or failure of this product.
• An ongoing dispute with Sopharma, the primary supplier of cytisinicline, regarding the engagement of third-party manufacturers, could lead to litigation or supply chain issues.
• Cytisinicline is derived from natural sources in limited locations outside the United States, posing risks to supply chain stability and quantity.
• Sopharma's manufacturing facilities have not been FDA inspected, which could delay or prevent regulatory approval if they fail to meet standards.
• Cytisinicline is not eligible for composition of matter patents in the U.S. as it is naturally occurring, potentially limiting long-term market exclusivity against generic versions or alternative third-party sales.

Risks

• Failure to obtain additional financing when needed, especially given the challenging current financing environment for biotechnology companies.
• Substantial debt ($10.0 million principal as of June 30, 2025) could impair financial flexibility and access to capital, with risks of default if unable to service obligations.
• Cytisinicline is the sole product candidate, and there is no guarantee of successful FDA or other regulatory agency approval for commercialization.
• Dependence on securing sufficient quantities of cytisinicline from natural sources (trees and plants) in limited locations outside the United States, with no guarantee of continued supply or exportation.
• Reliance on third-party manufacturers (Sopharma) carries risks of disputes, failure to obtain FDA approval, insufficient quantities, or quality issues.
• The FDA may require additional clinical or nonclinical studies for cytisinicline, or may not grant marketing approval at all.
• Cytisinicline may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial viability, or result in negative consequences post-approval.
• Difficulty in evaluating the current business, predicting prospects, and forecasting financial performance and growth due to limited operating history and no product sales revenue.
• Substantial competition from major pharmaceutical and biotechnology companies with greater financial and other resources.
• Clinical trials may not uncover all possible adverse events, potentially leading to issues post-market approval.
• Exposure to product liability claims if cytisinicline harms patients, potentially leading to substantial liability and costs.
• Business may be negatively affected by weather conditions, natural disasters, and availability of natural resources impacting cytisinicline supply.
• Risk of misallocating financial and human resources to less profitable programs or product candidates.
• Ongoing regulatory requirements post-approval, including cGMP compliance and post-marketing studies, are costly and non-compliance could lead to penalties or withdrawal of approvals.
• Subject to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, with potential for substantial penalties for non-compliance.
• Risk of misconduct by employees, independent contractors, consultants, or commercial partners.
• Breakthrough Therapy designation does not guarantee faster development, regulatory review, or approval for the vaping/e-cigarette cessation indication.
• Internal computer systems or those of third-party collaborators may fail or suffer security breaches and cyber-attacks, disrupting development programs.
• Risks associated with the integration and use of Artificial Intelligence (AI) tools, including legal, regulatory, and reputational risks.
• Inability to establish or maintain necessary third-party relationships for development or commercialization.
• Inability to realize potential benefits from collaborations, which may limit profit share or require relinquishing valuable rights.
• Inability to establish distribution, marketing, and sales capabilities, which are critical for commercialization.
• Failure to obtain or maintain adequate reimbursement or insurance coverage for products could limit marketability and revenue generation.
• Sopharma may breach its supply agreement and sell cytisinicline into the company's territories, negatively impacting commercialization efforts.
• Illegal distribution and sale of counterfeit versions of cytisinicline or alternative third-party distribution could harm financial performance or reputation.
• Inability to identify, license, discover, develop, or commercialize additional product candidates beyond cytisinicline.
• Subject to U.S. and foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws.
• Inability to maintain effective proprietary rights for product candidates, relying primarily on trade secret protection and confidentiality agreements.
• Third-party claims of intellectual property infringement may prevent or delay development and commercialization efforts.
• Changes in patent law could diminish the value of patents, impairing the ability to protect product candidates.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Inability to protect intellectual property rights throughout the world due to varying legal protections and costs.
• Volatility in the price of common stock due to various factors, including clinical trial results, regulatory approvals, and market conditions.
• Risk of securities class action litigation following stock price declines.
• Costs and demands associated with complying with laws and regulations affecting public companies.
• Shareholder activism could disrupt business operations.
• Anti-takeover provisions under Delaware law could make an acquisition more difficult.
• Bylaws' exclusive forum provision for disputes could limit stockholders' ability to choose a favorable judicial forum.
• Failure to maintain effective internal control over financial reporting could adversely affect reputation, results, and financial condition.
• Pre-merger net operating loss carryforwards and certain other tax attributes are subject to limitations under Section 382 of the U.S. Internal Revenue Code.
• U.S. federal tax reform and changes in other tax laws could increase the tax burden and adversely affect business and financial condition.

Future Outlook

The company plans to commence commercial sales of cytisinicline in the United States in the second half of 2026, if approved by the FDA. It intends to initiate Phase 3 clinical development for vaping cessation, contingent on funding, with study evaluations targeted for completion approximately 12 months after initiation. The company expects to incur substantial additional losses and increasing operating expenses for the foreseeable future as it continues clinical development and prepares for commercialization. Existing cash, cash equivalents, and marketable securities are projected to fund current operating expenses and capital expenditures into the second half of 2026.

Management Comments

• "We believe cytisinicline represents a unique opportunity to significantly impact global health by addressing the considerable unmet need among millions of smokers and e-cigarettes users."
• "If approved by the FDA, it may become one of the first new prescription medicines in nearly two decades aimed at aiding individuals in overcoming nicotine dependence."
• "We believe cytisinicline is differentiated from existing smoking cessation treatments given its combination of efficacy, well-tolerated safety profile, and a shorter therapy duration, as demonstrated in clinical trials."
• "We believe we will be able to commercialize independently in the U.S. market by focusing our marketing and sales efforts on highly targeted prescriber and patient audiences."
• "We are planning to launch by utilizing a well-established marketing technology infrastructure and embedding AI tools to enhance targeting, decision making, and performance metrics."
• "Launch planning and readiness activities are underway, leveraging our integrated agency partnership with Omnicom, with teams established for key functional areas including market access, medical education, prescriber and patient marketing, and digital infrastructure."
• "Field-based and virtual sales representatives will supplement digital promotional efforts."
• "We recently communicated to Sopharma that we had concerns regarding their ability to pass an FDA pre-approval inspection and that if those concerns were not resolved, we planned to engage third-party manufacturers and include such manufacturers in our NDA, until such time that Sopharma is able to pass an FDA inspection."
• "Sopharma has alleged that our engagement of third-party manufacturers is a breach of our agreement, which we have disputed and have proposed steps to resolve."
• "We believe that our existing cash, cash equivalents and marketable securities will be sufficient for us to fund our current operating expenses and capital expenditures into the second half of 2026."

Industry Context

The company operates within the highly competitive pharmaceutical and biotechnology industries, specifically targeting the global nicotine dependence epidemic, which includes 29 million adult combustible cigarette smokers and 17 million adult e-cigarette users in the U.S. alone. Tobacco use is a leading cause of preventable death, highlighting a significant unmet medical need. The focus on e-cigarette cessation is particularly relevant as there are currently no FDA-approved drug therapies for this indication, positioning cytisinicline for a potential first-to-market advantage if approved. The industry faces increasing pressure from managed healthcare, cost-containment initiatives, and legislative changes like the Inflation Reduction Act, which could impact drug pricing and reimbursement. The regulatory environment is also subject to uncertainty, including potential impacts from changes in judicial deference (Chevron doctrine reversal) and government shutdowns, which could affect FDA review timelines. The company's reliance on natural sourcing for cytisinicline and third-party manufacturing exposes it to supply chain risks, a common challenge in the pharmaceutical sector, further highlighted by recent issues like nitrosamine impurities in other smoking cessation drugs.

Legal Proceedings

• Sopharma has alleged that the company's engagement of third-party manufacturers is a breach of their agreement, which the company has disputed and proposed steps to resolve. This dispute may result in litigation.
• The company is at risk of securities class action litigation, which has historically been brought against companies following declines in stock price or clinical trial announcements.
• The company may be subject to government investigations of alleged violations of law, which would require significant time and resources and could generate adverse publicity.

Stakeholder Impact

• Shareholders: Potential for significant dilution from recent and future equity offerings; stock price volatility; potential for capital appreciation if cytisinicline is approved and successfully commercialized; risk of substantial losses if the product fails.
• Employees: Increased headcount and compensation expenses for commercialization efforts; stock-based compensation as a significant component of remuneration; risk of job loss if the company's product development or commercialization efforts are unsuccessful.
• Future Customers (Patients): Potential access to a new prescription medicine for smoking and e-cigarette cessation, offering a differentiated profile with potential for improved health outcomes.
• Suppliers: Continued reliance on Sopharma for cytisinicline supply, with potential for disputes or supply interruptions; engagement of new third-party manufacturers for API supply.
• Creditors: The New Convertible Term Loan provides financing but also imposes restrictive covenants and repayment obligations, secured by substantially all company assets (excluding intellectual property).

Next Steps

• FDA review of the New Drug Application (NDA) for cytisinicline for smoking cessation.
• Potential initiation of Phase 3 clinical development for vaping cessation, dependent on availability of funding.
• Target enrollment and completion of vaping cessation study evaluations approximately 12 months after study initiation.
• Provide cumulative one-year ORCA-OL exposure data to the FDA prior to potential product approval.
• Planned commencement of commercial sales of cytisinicline in the United States in the second half of 2026, if approved.
• Potential exploration of additional indications for the treatment of nicotine dependence in the future.
• Potential drawdowns of additional tranches of the New Convertible Term Loan (up to $10.0 million) upon meeting specified conditions.
• Potential sales of common stock under the Jefferies Open Market Sale Agreement (up to $50.0 million available).

Key Dates

Recommendation

The company has achieved critical milestones with the NDA submission for smoking cessation and Breakthrough Therapy designation for vaping cessation, significantly de-risking its primary asset. The successful capital raise provides a runway into H2 2026, addressing immediate liquidity concerns. However, the company remains pre-revenue with increasing operating losses, and its success is entirely dependent on a single product candidate. The ongoing dispute with Sopharma regarding manufacturing and the inherent risks of regulatory approval and commercialization for a novel drug, especially one derived from natural sources with potential supply chain vulnerabilities, warrant caution. While there's significant upside potential if cytisinicline gains approval and market acceptance, the risks associated with a single-asset, pre-commercial biotech, coupled with the Sopharma dispute, suggest a 'hold' position for investors to monitor regulatory outcomes and commercialization progress before committing further capital.

Keywords

Cytisinicline, Smoking Cessation, Vaping Cessation, Nicotine Dependence, FDA NDA, Breakthrough Therapy, Clinical Trials, Pharmaceutical, Biotechnology, Drug Development, SEC Filing, 10-Q, Public Offering, Convertible Debt, Sopharma, ORCA-OL, Commercialization